nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2A—enteric nervous system—Crohn's disease	0.015	0.366	CbGeAlD
Duloxetine—HTR2A—myenteric nerve plexus—Crohn's disease	0.0113	0.277	CbGeAlD
Duloxetine—NPY1R—mammalian vulva—Crohn's disease	0.0048	0.117	CbGeAlD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00258	0.00377	CcSEcCtD
Duloxetine—Blood creatinine increased—Mesalazine—Crohn's disease	0.00257	0.00377	CcSEcCtD
Duloxetine—Pancreatitis—Azathioprine—Crohn's disease	0.00255	0.00374	CcSEcCtD
Duloxetine—Liver function test abnormal—Mesalazine—Crohn's disease	0.00253	0.00371	CcSEcCtD
Duloxetine—Abdominal pain upper—Mesalazine—Crohn's disease	0.00251	0.00367	CcSEcCtD
Duloxetine—Orthostatic hypotension—Mesalazine—Crohn's disease	0.00251	0.00367	CcSEcCtD
Duloxetine—Abdominal discomfort—Azathioprine—Crohn's disease	0.0025	0.00366	CcSEcCtD
Duloxetine—Oedema—Mercaptopurine—Crohn's disease	0.00249	0.00364	CcSEcCtD
Duloxetine—Breast disorder—Mesalazine—Crohn's disease	0.00248	0.00363	CcSEcCtD
Duloxetine—Cramp muscle—Mesalazine—Crohn's disease	0.00247	0.00362	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00247	0.00362	CcSEcCtD
Duloxetine—Nasopharyngitis—Mesalazine—Crohn's disease	0.00246	0.00359	CcSEcCtD
Duloxetine—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00243	0.00356	CcSEcCtD
Duloxetine—Gastritis—Mesalazine—Crohn's disease	0.00243	0.00356	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00242	0.00355	CcSEcCtD
Duloxetine—Skin disorder—Mercaptopurine—Crohn's disease	0.00241	0.00354	CcSEcCtD
Duloxetine—Endocrine disorder—Prednisone—Crohn's disease	0.00241	0.00353	CcSEcCtD
Duloxetine—NPY1R—lymph node—Crohn's disease	0.0024	0.0588	CbGeAlD
Duloxetine—Dysphagia—Mesalazine—Crohn's disease	0.00237	0.00347	CcSEcCtD
Duloxetine—Influenza—Mesalazine—Crohn's disease	0.00237	0.00347	CcSEcCtD
Duloxetine—Anorexia—Mercaptopurine—Crohn's disease	0.00237	0.00347	CcSEcCtD
Duloxetine—Pancreatitis—Mesalazine—Crohn's disease	0.00233	0.00341	CcSEcCtD
Duloxetine—Infestation—Azathioprine—Crohn's disease	0.00232	0.0034	CcSEcCtD
Duloxetine—Infestation NOS—Azathioprine—Crohn's disease	0.00232	0.0034	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.0023	0.00337	CcSEcCtD
Duloxetine—Contusion—Prednisone—Crohn's disease	0.00229	0.00336	CcSEcCtD
Duloxetine—Abdominal discomfort—Mesalazine—Crohn's disease	0.00227	0.00333	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00227	0.00332	CcSEcCtD
Duloxetine—Dysuria—Mesalazine—Crohn's disease	0.00222	0.00325	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00221	0.00323	CcSEcCtD
Duloxetine—Hepatobiliary disease—Azathioprine—Crohn's disease	0.0022	0.00322	CcSEcCtD
Duloxetine—Pollakiuria—Mesalazine—Crohn's disease	0.00219	0.00321	CcSEcCtD
Duloxetine—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00217	0.00317	CcSEcCtD
Duloxetine—Decreased appetite—Mercaptopurine—Crohn's disease	0.00216	0.00316	CcSEcCtD
Duloxetine—Weight increased—Mesalazine—Crohn's disease	0.00216	0.00316	CcSEcCtD
Duloxetine—Weight decreased—Mesalazine—Crohn's disease	0.00215	0.00314	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00215	0.00314	CcSEcCtD
Duloxetine—Infestation—Mesalazine—Crohn's disease	0.00212	0.0031	CcSEcCtD
Duloxetine—Infestation NOS—Mesalazine—Crohn's disease	0.00212	0.0031	CcSEcCtD
Duloxetine—Hypercholesterolaemia—Prednisone—Crohn's disease	0.00212	0.0031	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.0021	0.00307	CcSEcCtD
Duloxetine—Haemoglobin—Azathioprine—Crohn's disease	0.0021	0.00307	CcSEcCtD
Duloxetine—Haemorrhage—Azathioprine—Crohn's disease	0.00209	0.00305	CcSEcCtD
Duloxetine—Renal failure—Mesalazine—Crohn's disease	0.00208	0.00305	CcSEcCtD
Duloxetine—Stomatitis—Mesalazine—Crohn's disease	0.00206	0.00302	CcSEcCtD
Duloxetine—Jaundice—Mesalazine—Crohn's disease	0.00206	0.00302	CcSEcCtD
Duloxetine—Conjunctivitis—Mesalazine—Crohn's disease	0.00206	0.00301	CcSEcCtD
Duloxetine—Urinary tract infection—Mesalazine—Crohn's disease	0.00206	0.00301	CcSEcCtD
Duloxetine—Hepatobiliary disease—Mesalazine—Crohn's disease	0.002	0.00293	CcSEcCtD
Duloxetine—Epistaxis—Mesalazine—Crohn's disease	0.002	0.00292	CcSEcCtD
Duloxetine—Erythema multiforme—Azathioprine—Crohn's disease	0.00197	0.00289	CcSEcCtD
Duloxetine—Body temperature increased—Mercaptopurine—Crohn's disease	0.00197	0.00288	CcSEcCtD
Duloxetine—Haemoglobin—Mesalazine—Crohn's disease	0.00191	0.0028	CcSEcCtD
Duloxetine—Hepatitis—Mesalazine—Crohn's disease	0.0019	0.00278	CcSEcCtD
Duloxetine—Haemorrhage—Mesalazine—Crohn's disease	0.0019	0.00278	CcSEcCtD
Duloxetine—Pharyngitis—Mesalazine—Crohn's disease	0.00189	0.00276	CcSEcCtD
Duloxetine—Immune system disorder—Azathioprine—Crohn's disease	0.00188	0.00276	CcSEcCtD
Duloxetine—Mediastinal disorder—Azathioprine—Crohn's disease	0.00188	0.00275	CcSEcCtD
Duloxetine—Urinary tract disorder—Mesalazine—Crohn's disease	0.00188	0.00275	CcSEcCtD
Duloxetine—Oedema peripheral—Mesalazine—Crohn's disease	0.00187	0.00274	CcSEcCtD
Duloxetine—Chills—Azathioprine—Crohn's disease	0.00187	0.00274	CcSEcCtD
Duloxetine—Connective tissue disorder—Mesalazine—Crohn's disease	0.00187	0.00273	CcSEcCtD
Duloxetine—Arrhythmia—Azathioprine—Crohn's disease	0.00186	0.00273	CcSEcCtD
Duloxetine—Urethral disorder—Mesalazine—Crohn's disease	0.00186	0.00273	CcSEcCtD
Duloxetine—Alopecia—Azathioprine—Crohn's disease	0.00184	0.0027	CcSEcCtD
Duloxetine—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00183	0.00268	CcSEcCtD
Duloxetine—Ecchymosis—Prednisone—Crohn's disease	0.00181	0.00265	CcSEcCtD
Duloxetine—Erythema multiforme—Mesalazine—Crohn's disease	0.0018	0.00263	CcSEcCtD
Duloxetine—Eye disorder—Mesalazine—Crohn's disease	0.00177	0.0026	CcSEcCtD
Duloxetine—Tinnitus—Mesalazine—Crohn's disease	0.00177	0.00259	CcSEcCtD
Duloxetine—Cardiac disorder—Mesalazine—Crohn's disease	0.00176	0.00258	CcSEcCtD
Duloxetine—Angiopathy—Mesalazine—Crohn's disease	0.00172	0.00252	CcSEcCtD
Duloxetine—Immune system disorder—Mesalazine—Crohn's disease	0.00172	0.00251	CcSEcCtD
Duloxetine—Mediastinal disorder—Mesalazine—Crohn's disease	0.00171	0.00251	CcSEcCtD
Duloxetine—Chills—Mesalazine—Crohn's disease	0.0017	0.0025	CcSEcCtD
Duloxetine—Diarrhoea—Mercaptopurine—Crohn's disease	0.0017	0.00249	CcSEcCtD
Duloxetine—Ill-defined disorder—Azathioprine—Crohn's disease	0.00168	0.00247	CcSEcCtD
Duloxetine—Alopecia—Mesalazine—Crohn's disease	0.00168	0.00246	CcSEcCtD
Duloxetine—Anaemia—Azathioprine—Crohn's disease	0.00168	0.00246	CcSEcCtD
Duloxetine—Diabetes mellitus—Prednisone—Crohn's disease	0.00167	0.00245	CcSEcCtD
Duloxetine—Mental disorder—Mesalazine—Crohn's disease	0.00166	0.00244	CcSEcCtD
Duloxetine—Erythema—Mesalazine—Crohn's disease	0.00165	0.00242	CcSEcCtD
Duloxetine—Malaise—Azathioprine—Crohn's disease	0.00164	0.0024	CcSEcCtD
Duloxetine—Flatulence—Mesalazine—Crohn's disease	0.00163	0.00239	CcSEcCtD
Duloxetine—Leukopenia—Azathioprine—Crohn's disease	0.00162	0.00238	CcSEcCtD
Duloxetine—SLC6A4—digestive system—Crohn's disease	0.00162	0.0397	CbGeAlD
Duloxetine—Tension—Mesalazine—Crohn's disease	0.00162	0.00238	CcSEcCtD
Duloxetine—Dysgeusia—Mesalazine—Crohn's disease	0.00162	0.00237	CcSEcCtD
Duloxetine—Nervousness—Mesalazine—Crohn's disease	0.00161	0.00235	CcSEcCtD
Duloxetine—Cardiac failure congestive—Prednisone—Crohn's disease	0.0016	0.00235	CcSEcCtD
Duloxetine—Back pain—Mesalazine—Crohn's disease	0.0016	0.00234	CcSEcCtD
Duloxetine—Muscle spasms—Mesalazine—Crohn's disease	0.00159	0.00233	CcSEcCtD
Duloxetine—Vomiting—Mercaptopurine—Crohn's disease	0.00158	0.00231	CcSEcCtD
Duloxetine—Rash—Mercaptopurine—Crohn's disease	0.00157	0.0023	CcSEcCtD
Duloxetine—Dermatitis—Mercaptopurine—Crohn's disease	0.00157	0.00229	CcSEcCtD
Duloxetine—Vision blurred—Mesalazine—Crohn's disease	0.00156	0.00228	CcSEcCtD
Duloxetine—Tremor—Mesalazine—Crohn's disease	0.00155	0.00227	CcSEcCtD
Duloxetine—Increased appetite—Prednisone—Crohn's disease	0.00155	0.00226	CcSEcCtD
Duloxetine—Arthralgia—Azathioprine—Crohn's disease	0.00155	0.00226	CcSEcCtD
Duloxetine—Myalgia—Azathioprine—Crohn's disease	0.00155	0.00226	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.00153	0.00225	CcSEcCtD
Duloxetine—Ill-defined disorder—Mesalazine—Crohn's disease	0.00153	0.00225	CcSEcCtD
Duloxetine—Anaemia—Mesalazine—Crohn's disease	0.00153	0.00224	CcSEcCtD
Duloxetine—Discomfort—Azathioprine—Crohn's disease	0.00153	0.00224	CcSEcCtD
Duloxetine—Angioedema—Mesalazine—Crohn's disease	0.00151	0.00221	CcSEcCtD
Duloxetine—Malaise—Mesalazine—Crohn's disease	0.00149	0.00218	CcSEcCtD
Duloxetine—Cardiac failure—Prednisone—Crohn's disease	0.00149	0.00218	CcSEcCtD
Duloxetine—Vertigo—Mesalazine—Crohn's disease	0.00149	0.00217	CcSEcCtD
Duloxetine—Syncope—Mesalazine—Crohn's disease	0.00148	0.00217	CcSEcCtD
Duloxetine—Lethargy—Prednisone—Crohn's disease	0.00148	0.00217	CcSEcCtD
Duloxetine—Leukopenia—Mesalazine—Crohn's disease	0.00148	0.00217	CcSEcCtD
Duloxetine—Nausea—Mercaptopurine—Crohn's disease	0.00148	0.00216	CcSEcCtD
Duloxetine—Infection—Azathioprine—Crohn's disease	0.00147	0.00215	CcSEcCtD
Duloxetine—Palpitations—Mesalazine—Crohn's disease	0.00146	0.00214	CcSEcCtD
Duloxetine—Loss of consciousness—Mesalazine—Crohn's disease	0.00145	0.00213	CcSEcCtD
Duloxetine—Osteoarthritis—Prednisone—Crohn's disease	0.00145	0.00213	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.00145	0.00213	CcSEcCtD
Duloxetine—Thrombocytopenia—Azathioprine—Crohn's disease	0.00145	0.00212	CcSEcCtD
Duloxetine—Cough—Mesalazine—Crohn's disease	0.00144	0.00211	CcSEcCtD
Duloxetine—Skin disorder—Azathioprine—Crohn's disease	0.00144	0.00211	CcSEcCtD
Duloxetine—Affect lability—Prednisone—Crohn's disease	0.00143	0.00209	CcSEcCtD
Duloxetine—Hypertension—Mesalazine—Crohn's disease	0.00143	0.00209	CcSEcCtD
Duloxetine—Chest pain—Mesalazine—Crohn's disease	0.00141	0.00206	CcSEcCtD
Duloxetine—Myalgia—Mesalazine—Crohn's disease	0.00141	0.00206	CcSEcCtD
Duloxetine—Arthralgia—Mesalazine—Crohn's disease	0.00141	0.00206	CcSEcCtD
Duloxetine—Anxiety—Mesalazine—Crohn's disease	0.0014	0.00205	CcSEcCtD
Duloxetine—Face oedema—Prednisone—Crohn's disease	0.0014	0.00205	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.0014	0.00205	CcSEcCtD
Duloxetine—Discomfort—Mesalazine—Crohn's disease	0.00139	0.00204	CcSEcCtD
Duloxetine—Irritability—Prednisone—Crohn's disease	0.00139	0.00203	CcSEcCtD
Duloxetine—Dry mouth—Mesalazine—Crohn's disease	0.00138	0.00202	CcSEcCtD
Duloxetine—Mood swings—Prednisone—Crohn's disease	0.00138	0.00201	CcSEcCtD
Duloxetine—Confusional state—Mesalazine—Crohn's disease	0.00136	0.00199	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00135	0.00198	CcSEcCtD
Duloxetine—Oedema—Mesalazine—Crohn's disease	0.00135	0.00198	CcSEcCtD
Duloxetine—Anaphylactic shock—Mesalazine—Crohn's disease	0.00135	0.00198	CcSEcCtD
Duloxetine—Infection—Mesalazine—Crohn's disease	0.00134	0.00196	CcSEcCtD
Duloxetine—Shock—Mesalazine—Crohn's disease	0.00133	0.00194	CcSEcCtD
Duloxetine—Nervous system disorder—Mesalazine—Crohn's disease	0.00132	0.00194	CcSEcCtD
Duloxetine—Thrombocytopenia—Mesalazine—Crohn's disease	0.00132	0.00193	CcSEcCtD
Duloxetine—Tachycardia—Mesalazine—Crohn's disease	0.00132	0.00193	CcSEcCtD
Duloxetine—Skin disorder—Mesalazine—Crohn's disease	0.00131	0.00192	CcSEcCtD
Duloxetine—Hyperhidrosis—Mesalazine—Crohn's disease	0.0013	0.00191	CcSEcCtD
Duloxetine—Anorexia—Mesalazine—Crohn's disease	0.00129	0.00188	CcSEcCtD
Duloxetine—Muscular weakness—Prednisone—Crohn's disease	0.00128	0.00188	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.00128	0.00188	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00128	0.00187	CcSEcCtD
Duloxetine—Pancreatitis—Prednisone—Crohn's disease	0.00123	0.0018	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00123	0.0018	CcSEcCtD
Duloxetine—Sweating increased—Prednisone—Crohn's disease	0.00122	0.00179	CcSEcCtD
Duloxetine—Feeling abnormal—Azathioprine—Crohn's disease	0.00122	0.00179	CcSEcCtD
Duloxetine—Insomnia—Mesalazine—Crohn's disease	0.00122	0.00179	CcSEcCtD
Duloxetine—Paraesthesia—Mesalazine—Crohn's disease	0.00121	0.00177	CcSEcCtD
Duloxetine—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00121	0.00177	CcSEcCtD
Duloxetine—Somnolence—Mesalazine—Crohn's disease	0.0012	0.00176	CcSEcCtD
Duloxetine—Dyspepsia—Mesalazine—Crohn's disease	0.00119	0.00174	CcSEcCtD
Duloxetine—Decreased appetite—Mesalazine—Crohn's disease	0.00117	0.00172	CcSEcCtD
Duloxetine—Body temperature increased—Azathioprine—Crohn's disease	0.00117	0.00171	CcSEcCtD
Duloxetine—Abdominal pain—Azathioprine—Crohn's disease	0.00117	0.00171	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00116	0.00171	CcSEcCtD
Duloxetine—Fatigue—Mesalazine—Crohn's disease	0.00116	0.0017	CcSEcCtD
Duloxetine—Erectile dysfunction—Prednisone—Crohn's disease	0.00116	0.00169	CcSEcCtD
Duloxetine—Pain—Mesalazine—Crohn's disease	0.00115	0.00169	CcSEcCtD
Duloxetine—Constipation—Mesalazine—Crohn's disease	0.00115	0.00169	CcSEcCtD
Duloxetine—Weight increased—Prednisone—Crohn's disease	0.00114	0.00167	CcSEcCtD
Duloxetine—Weight decreased—Prednisone—Crohn's disease	0.00114	0.00166	CcSEcCtD
Duloxetine—Hyperglycaemia—Prednisone—Crohn's disease	0.00113	0.00166	CcSEcCtD
Duloxetine—HTR2A—epithelium—Crohn's disease	0.00113	0.0276	CbGeAlD
Duloxetine—Feeling abnormal—Mesalazine—Crohn's disease	0.00111	0.00163	CcSEcCtD
Duloxetine—Acute coronary syndrome—Prednisone—Crohn's disease	0.0011	0.00162	CcSEcCtD
Duloxetine—Gastrointestinal pain—Mesalazine—Crohn's disease	0.0011	0.00162	CcSEcCtD
Duloxetine—CYP1A2—digestive system—Crohn's disease	0.0011	0.0268	CbGeAlD
Duloxetine—Myocardial infarction—Prednisone—Crohn's disease	0.0011	0.00161	CcSEcCtD
Duloxetine—Hypersensitivity—Azathioprine—Crohn's disease	0.00109	0.0016	CcSEcCtD
Duloxetine—HTR2A—smooth muscle tissue—Crohn's disease	0.00109	0.0266	CbGeAlD
Duloxetine—Urticaria—Mesalazine—Crohn's disease	0.00107	0.00157	CcSEcCtD
Duloxetine—Abdominal pain—Mesalazine—Crohn's disease	0.00107	0.00156	CcSEcCtD
Duloxetine—Body temperature increased—Mesalazine—Crohn's disease	0.00107	0.00156	CcSEcCtD
Duloxetine—Diarrhoea—Azathioprine—Crohn's disease	0.00101	0.00148	CcSEcCtD
Duloxetine—Haemoglobin—Prednisone—Crohn's disease	0.00101	0.00148	CcSEcCtD
Duloxetine—Haemorrhage—Prednisone—Crohn's disease	0.001	0.00147	CcSEcCtD
Duloxetine—Hallucination—Prednisone—Crohn's disease	0.001	0.00146	CcSEcCtD
Duloxetine—Hypersensitivity—Mesalazine—Crohn's disease	0.000994	0.00146	CcSEcCtD
Duloxetine—Connective tissue disorder—Prednisone—Crohn's disease	0.000987	0.00145	CcSEcCtD
Duloxetine—Dizziness—Azathioprine—Crohn's disease	0.00098	0.00143	CcSEcCtD
Duloxetine—Asthenia—Mesalazine—Crohn's disease	0.000968	0.00142	CcSEcCtD
Duloxetine—Pruritus—Mesalazine—Crohn's disease	0.000955	0.0014	CcSEcCtD
Duloxetine—Vomiting—Azathioprine—Crohn's disease	0.000942	0.00138	CcSEcCtD
Duloxetine—Eye disorder—Prednisone—Crohn's disease	0.000939	0.00138	CcSEcCtD
Duloxetine—Rash—Azathioprine—Crohn's disease	0.000934	0.00137	CcSEcCtD
Duloxetine—Dermatitis—Azathioprine—Crohn's disease	0.000933	0.00137	CcSEcCtD
Duloxetine—Flushing—Prednisone—Crohn's disease	0.000933	0.00137	CcSEcCtD
Duloxetine—Headache—Azathioprine—Crohn's disease	0.000928	0.00136	CcSEcCtD
Duloxetine—Diarrhoea—Mesalazine—Crohn's disease	0.000923	0.00135	CcSEcCtD
Duloxetine—Angiopathy—Prednisone—Crohn's disease	0.000912	0.00133	CcSEcCtD
Duloxetine—Immune system disorder—Prednisone—Crohn's disease	0.000908	0.00133	CcSEcCtD
Duloxetine—Arrhythmia—Prednisone—Crohn's disease	0.000898	0.00131	CcSEcCtD
Duloxetine—Dizziness—Mesalazine—Crohn's disease	0.000892	0.00131	CcSEcCtD
Duloxetine—Alopecia—Prednisone—Crohn's disease	0.000888	0.0013	CcSEcCtD
Duloxetine—Mental disorder—Prednisone—Crohn's disease	0.00088	0.00129	CcSEcCtD
Duloxetine—Nausea—Azathioprine—Crohn's disease	0.00088	0.00129	CcSEcCtD
Duloxetine—Malnutrition—Prednisone—Crohn's disease	0.000875	0.00128	CcSEcCtD
Duloxetine—Erythema—Prednisone—Crohn's disease	0.000875	0.00128	CcSEcCtD
Duloxetine—HTR2A—digestive system—Crohn's disease	0.000859	0.021	CbGeAlD
Duloxetine—Vomiting—Mesalazine—Crohn's disease	0.000858	0.00126	CcSEcCtD
Duloxetine—Rash—Mesalazine—Crohn's disease	0.000851	0.00125	CcSEcCtD
Duloxetine—Dermatitis—Mesalazine—Crohn's disease	0.00085	0.00124	CcSEcCtD
Duloxetine—Headache—Mesalazine—Crohn's disease	0.000845	0.00124	CcSEcCtD
Duloxetine—Vision blurred—Prednisone—Crohn's disease	0.000824	0.00121	CcSEcCtD
Duloxetine—SLC6A2—lymph node—Crohn's disease	0.000816	0.0199	CbGeAlD
Duloxetine—Ill-defined disorder—Prednisone—Crohn's disease	0.000812	0.00119	CcSEcCtD
Duloxetine—Anaemia—Prednisone—Crohn's disease	0.000809	0.00118	CcSEcCtD
Duloxetine—Agitation—Prednisone—Crohn's disease	0.000804	0.00118	CcSEcCtD
Duloxetine—Nausea—Mesalazine—Crohn's disease	0.000801	0.00117	CcSEcCtD
Duloxetine—Angioedema—Prednisone—Crohn's disease	0.000799	0.00117	CcSEcCtD
Duloxetine—Malaise—Prednisone—Crohn's disease	0.000789	0.00116	CcSEcCtD
Duloxetine—Vertigo—Prednisone—Crohn's disease	0.000786	0.00115	CcSEcCtD
Duloxetine—Syncope—Prednisone—Crohn's disease	0.000784	0.00115	CcSEcCtD
Duloxetine—CYP2D6—digestive system—Crohn's disease	0.000782	0.0191	CbGeAlD
Duloxetine—Loss of consciousness—Prednisone—Crohn's disease	0.000769	0.00113	CcSEcCtD
Duloxetine—Convulsion—Prednisone—Crohn's disease	0.000758	0.00111	CcSEcCtD
Duloxetine—Hypertension—Prednisone—Crohn's disease	0.000755	0.00111	CcSEcCtD
Duloxetine—Arthralgia—Prednisone—Crohn's disease	0.000745	0.00109	CcSEcCtD
Duloxetine—Myalgia—Prednisone—Crohn's disease	0.000745	0.00109	CcSEcCtD
Duloxetine—Anxiety—Prednisone—Crohn's disease	0.000742	0.00109	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.00074	0.00108	CcSEcCtD
Duloxetine—Discomfort—Prednisone—Crohn's disease	0.000736	0.00108	CcSEcCtD
Duloxetine—Oedema—Prednisone—Crohn's disease	0.000714	0.00105	CcSEcCtD
Duloxetine—Anaphylactic shock—Prednisone—Crohn's disease	0.000714	0.00105	CcSEcCtD
Duloxetine—Infection—Prednisone—Crohn's disease	0.000709	0.00104	CcSEcCtD
Duloxetine—Shock—Prednisone—Crohn's disease	0.000702	0.00103	CcSEcCtD
Duloxetine—Nervous system disorder—Prednisone—Crohn's disease	0.0007	0.00103	CcSEcCtD
Duloxetine—Tachycardia—Prednisone—Crohn's disease	0.000697	0.00102	CcSEcCtD
Duloxetine—Skin disorder—Prednisone—Crohn's disease	0.000693	0.00102	CcSEcCtD
Duloxetine—Hyperhidrosis—Prednisone—Crohn's disease	0.00069	0.00101	CcSEcCtD
Duloxetine—Anorexia—Prednisone—Crohn's disease	0.000681	0.000996	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.00065	0.000952	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000649	0.00235	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000649	0.00235	CbGpPWpGaD
Duloxetine—Insomnia—Prednisone—Crohn's disease	0.000646	0.000945	CcSEcCtD
Duloxetine—Paraesthesia—Prednisone—Crohn's disease	0.000641	0.000939	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—ACKR2—Crohn's disease	0.000639	0.00231	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.000639	0.00231	CbGpPWpGaD
Duloxetine—Dyspepsia—Prednisone—Crohn's disease	0.000628	0.00092	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000627	0.00227	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—GPR65—Crohn's disease	0.000625	0.00226	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—IL3—Crohn's disease	0.000623	0.00226	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000622	0.00225	CbGpPWpGaD
Duloxetine—Decreased appetite—Prednisone—Crohn's disease	0.000621	0.000909	CcSEcCtD
Duloxetine—Fatigue—Prednisone—Crohn's disease	0.000616	0.000901	CcSEcCtD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000612	0.00222	CbGpPWpGaD
Duloxetine—Constipation—Prednisone—Crohn's disease	0.000611	0.000894	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—MLN—Crohn's disease	0.000606	0.00219	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCR9—Crohn's disease	0.000603	0.00218	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000602	0.00218	CbGpPWpGaD
Duloxetine—Feeling abnormal—Prednisone—Crohn's disease	0.000588	0.000861	CcSEcCtD
Duloxetine—Gastrointestinal pain—Prednisone—Crohn's disease	0.000584	0.000855	CcSEcCtD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000575	0.00208	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000575	0.00208	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.000574	0.00208	CbGpPWpGaD
Duloxetine—Urticaria—Prednisone—Crohn's disease	0.000567	0.00083	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—IL3—Crohn's disease	0.000565	0.00205	CbGpPWpGaD
Duloxetine—Abdominal pain—Prednisone—Crohn's disease	0.000564	0.000826	CcSEcCtD
Duloxetine—Body temperature increased—Prednisone—Crohn's disease	0.000564	0.000826	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—GPR65—Crohn's disease	0.00056	0.00203	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—RASGRP1—Crohn's disease	0.000547	0.00198	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CCR6—Crohn's disease	0.000542	0.00196	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000539	0.00195	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000531	0.00192	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—GPX4—Crohn's disease	0.000531	0.00192	CbGpPWpGaD
Duloxetine—Hypersensitivity—Prednisone—Crohn's disease	0.000526	0.00077	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000524	0.0019	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCR9—Crohn's disease	0.000523	0.0019	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.000513	0.00186	CbGpPWpGaD
Duloxetine—Asthenia—Prednisone—Crohn's disease	0.000512	0.00075	CcSEcCtD
Duloxetine—Pruritus—Prednisone—Crohn's disease	0.000505	0.00074	CcSEcCtD
Duloxetine—HTR2A—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.000498	0.00181	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—MLN—Crohn's disease	0.000491	0.00178	CbGpPWpGaD
Duloxetine—Diarrhoea—Prednisone—Crohn's disease	0.000488	0.000715	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—GPR65—Crohn's disease	0.000486	0.00176	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—PTGER4—Crohn's disease	0.000477	0.00173	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CXCL8—Crohn's disease	0.000473	0.00171	CbGpPWpGaD
Duloxetine—Dizziness—Prednisone—Crohn's disease	0.000472	0.000691	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—ACKR2—Crohn's disease	0.000471	0.0017	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL10—Crohn's disease	0.000468	0.0017	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000468	0.00169	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCR9—Crohn's disease	0.000462	0.00167	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000461	0.00167	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000457	0.00166	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000455	0.00165	CbGpPWpGaD
Duloxetine—Vomiting—Prednisone—Crohn's disease	0.000454	0.000665	CcSEcCtD
Duloxetine—Rash—Prednisone—Crohn's disease	0.00045	0.000659	CcSEcCtD
Duloxetine—CYP1A2—Metapathway biotransformation—GPX4—Crohn's disease	0.00045	0.00163	CbGpPWpGaD
Duloxetine—Dermatitis—Prednisone—Crohn's disease	0.00045	0.000658	CcSEcCtD
Duloxetine—Headache—Prednisone—Crohn's disease	0.000447	0.000655	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—MLN—Crohn's disease	0.000446	0.00162	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.000446	0.00161	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCR6—Crohn's disease	0.000445	0.00161	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—IL2RA—Crohn's disease	0.000436	0.00158	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—GPR65—Crohn's disease	0.00043	0.00156	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—MLN—Crohn's disease	0.000427	0.00155	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	0.000425	0.00154	CbGpPWpGaD
Duloxetine—Nausea—Prednisone—Crohn's disease	0.000424	0.000621	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—CCR9—Crohn's disease	0.00042	0.00152	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ACKR2—Crohn's disease	0.000409	0.00148	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL1B—Crohn's disease	0.000408	0.00148	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000405	0.00147	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000404	0.00146	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RBX1—Crohn's disease	0.000403	0.00146	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000401	0.00145	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCR6—Crohn's disease	0.000399	0.00145	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL2RA—Crohn's disease	0.000396	0.00143	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTGER4—Crohn's disease	0.000392	0.00142	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—GPR65—Crohn's disease	0.00039	0.00141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MLN—Crohn's disease	0.000387	0.0014	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ACKR2—Crohn's disease	0.000378	0.00137	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	0.000367	0.00133	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000358	0.0013	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MLN—Crohn's disease	0.000358	0.0013	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—UBE2D1—Crohn's disease	0.000353	0.00128	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	0.000352	0.00128	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—PTGER4—Crohn's disease	0.000351	0.00127	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCR6—Crohn's disease	0.000347	0.00126	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RIPK2—Crohn's disease	0.000343	0.00124	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR9—Crohn's disease	0.000341	0.00123	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL3—Crohn's disease	0.000334	0.00121	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000329	0.00119	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	0.000328	0.00119	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TAGAP—Crohn's disease	0.000327	0.00119	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RASGRP1—Crohn's disease	0.000323	0.00117	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—GPR65—Crohn's disease	0.000317	0.00115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR9—Crohn's disease	0.000309	0.00112	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCR6—Crohn's disease	0.000306	0.00111	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PTGER4—Crohn's disease	0.000305	0.00111	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—Crohn's disease	0.000296	0.00107	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR9—Crohn's disease	0.000296	0.00107	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—JAK2—Crohn's disease	0.000293	0.00106	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SOCS1—Crohn's disease	0.000293	0.00106	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—GPR65—Crohn's disease	0.000287	0.00104	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—Crohn's disease	0.000286	0.00104	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RSPO3—Crohn's disease	0.000286	0.00104	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000282	0.00102	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TYK2—Crohn's disease	0.000279	0.00101	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCR6—Crohn's disease	0.000278	0.00101	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ACKR2—Crohn's disease	0.000278	0.00101	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—GPR65—Crohn's disease	0.000275	0.000996	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SEL1L—Crohn's disease	0.000271	0.000982	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PTGER4—Crohn's disease	0.00027	0.000977	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR9—Crohn's disease	0.000269	0.000972	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CXCL8—Crohn's disease	0.000268	0.000969	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—JAK2—Crohn's disease	0.000266	0.000964	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MLN—Crohn's disease	0.000264	0.000954	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000262	0.000949	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	0.000256	0.000927	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—Crohn's disease	0.000254	0.000919	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SMAD3—Crohn's disease	0.000253	0.000915	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.00025	0.000905	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—GPR65—Crohn's disease	0.00025	0.000904	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR9—Crohn's disease	0.000248	0.000898	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL1B—Crohn's disease	0.000246	0.00089	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTGER4—Crohn's disease	0.000245	0.000887	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCL8—Crohn's disease	0.000243	0.00088	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ACKR2—Crohn's disease	0.000241	0.000874	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TAGAP—Crohn's disease	0.000241	0.000873	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.00024	0.000869	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—Crohn's disease	0.000239	0.000865	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	0.000238	0.000861	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	0.000238	0.000861	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2RA—Crohn's disease	0.000234	0.000847	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—GPR65—Crohn's disease	0.000231	0.000835	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL3—Crohn's disease	0.00023	0.000832	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000229	0.000831	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MLN—Crohn's disease	0.000229	0.000829	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000228	0.000824	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR6—Crohn's disease	0.000226	0.000817	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000222	0.000805	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000217	0.000786	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RSPO3—Crohn's disease	0.000211	0.000763	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TAGAP—Crohn's disease	0.000209	0.000758	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL3—Crohn's disease	0.000209	0.000755	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR6—Crohn's disease	0.000205	0.000742	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RASGRP1—Crohn's disease	0.000202	0.000731	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SEL1L—Crohn's disease	0.0002	0.000723	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PTGER4—Crohn's disease	0.000199	0.000719	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR6—Crohn's disease	0.000196	0.000709	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—Crohn's disease	0.000195	0.000707	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000187	0.000677	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RSPO3—Crohn's disease	0.000183	0.000663	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR9—Crohn's disease	0.000183	0.000662	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTGER4—Crohn's disease	0.00018	0.000653	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—Crohn's disease	0.000178	0.000645	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR6—Crohn's disease	0.000178	0.000644	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000175	0.000634	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCL8—Crohn's disease	0.000175	0.000633	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SEL1L—Crohn's disease	0.000173	0.000628	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PTGER4—Crohn's disease	0.000172	0.000625	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GPR65—Crohn's disease	0.00017	0.000615	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL3—Crohn's disease	0.000169	0.000613	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000169	0.000612	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TYK2—Crohn's disease	0.000165	0.000597	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR6—Crohn's disease	0.000164	0.000595	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000164	0.000593	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2RA—Crohn's disease	0.000161	0.000583	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR9—Crohn's disease	0.000159	0.000574	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—JAK2—Crohn's disease	0.000157	0.00057	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTGER4—Crohn's disease	0.000157	0.000567	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL3—Crohn's disease	0.000154	0.000556	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RBX1—Crohn's disease	0.000149	0.000538	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RASGRP1—Crohn's disease	0.000149	0.000538	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	0.000148	0.000537	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GPR65—Crohn's disease	0.000147	0.000534	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL3—Crohn's disease	0.000147	0.000532	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000147	0.000531	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2RA—Crohn's disease	0.000146	0.000529	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ALB—Crohn's disease	0.000146	0.000527	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTGER4—Crohn's disease	0.000145	0.000524	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—Crohn's disease	0.000144	0.000521	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCL8—Crohn's disease	0.000144	0.00052	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000142	0.000515	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—Crohn's disease	0.000136	0.000494	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL3—Crohn's disease	0.000133	0.000483	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—UBE2D1—Crohn's disease	0.00013	0.000472	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RASGRP1—Crohn's disease	0.000129	0.000467	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ALB—Crohn's disease	0.000129	0.000467	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL8—Crohn's disease	0.000129	0.000466	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000128	0.000464	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RIPK2—Crohn's disease	0.000126	0.000458	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTMR3—Crohn's disease	0.000126	0.000457	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	0.000126	0.000455	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL3—Crohn's disease	0.000123	0.000446	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR6—Crohn's disease	0.000121	0.000438	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RASGRP1—Crohn's disease	0.000119	0.000432	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2RA—Crohn's disease	0.000118	0.000429	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT3—Crohn's disease	0.000115	0.000418	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL8—Crohn's disease	0.000112	0.000405	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000111	0.000403	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RBX1—Crohn's disease	0.000109	0.000396	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—JAK2—Crohn's disease	0.000108	0.000392	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SOCS1—Crohn's disease	0.000108	0.000391	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2RA—Crohn's disease	0.000108	0.00039	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTMR3—Crohn's disease	0.000107	0.000387	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTGER4—Crohn's disease	0.000107	0.000386	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR6—Crohn's disease	0.000105	0.000381	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TYK2—Crohn's disease	0.000103	0.000373	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2RA—Crohn's disease	0.000103	0.000373	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—Crohn's disease	9.87e-05	0.000357	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FADS1—Crohn's disease	9.83e-05	0.000356	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—JAK2—Crohn's disease	9.82e-05	0.000356	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—UBE2D1—Crohn's disease	9.6e-05	0.000348	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RBX1—Crohn's disease	9.5e-05	0.000344	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2RA—Crohn's disease	9.34e-05	0.000338	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SMAD3—Crohn's disease	9.32e-05	0.000338	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RIPK2—Crohn's disease	9.31e-05	0.000337	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTGER4—Crohn's disease	9.25e-05	0.000335	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX4—Crohn's disease	9.21e-05	0.000333	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL3—Crohn's disease	9.07e-05	0.000329	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—Crohn's disease	8.96e-05	0.000325	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCKR—Crohn's disease	8.89e-05	0.000322	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RASGRP1—Crohn's disease	8.78e-05	0.000318	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2RA—Crohn's disease	8.63e-05	0.000313	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—UBE2D1—Crohn's disease	8.33e-05	0.000302	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FADS1—Crohn's disease	8.33e-05	0.000302	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RIPK2—Crohn's disease	8.08e-05	0.000293	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—Crohn's disease	8.06e-05	0.000292	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—JAK2—Crohn's disease	7.96e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SOCS1—Crohn's disease	7.95e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL3—Crohn's disease	7.88e-05	0.000285	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX4—Crohn's disease	7.8e-05	0.000282	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RASGRP1—Crohn's disease	7.62e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TYK2—Crohn's disease	7.58e-05	0.000275	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCKR—Crohn's disease	7.53e-05	0.000273	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—Crohn's disease	7.27e-05	0.000263	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—JAK2—Crohn's disease	7.23e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—JAK2—Crohn's disease	6.92e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS1—Crohn's disease	6.9e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SMAD3—Crohn's disease	6.87e-05	0.000249	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—Crohn's disease	6.6e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TYK2—Crohn's disease	6.58e-05	0.000238	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2RA—Crohn's disease	6.36e-05	0.00023	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—Crohn's disease	6.31e-05	0.000229	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—JAK2—Crohn's disease	6.28e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TYK2—Crohn's disease	6.08e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SMAD3—Crohn's disease	5.96e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JAK2—Crohn's disease	5.8e-05	0.00021	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—Crohn's disease	5.73e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2RA—Crohn's disease	5.52e-05	0.0002	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	5.38e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—Crohn's disease	5.3e-05	0.000192	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—Crohn's disease	5.04e-05	0.000182	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.71e-05	0.000171	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TYK2—Crohn's disease	4.48e-05	0.000162	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JAK2—Crohn's disease	4.27e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—Crohn's disease	4.26e-05	0.000154	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—Crohn's disease	3.9e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TYK2—Crohn's disease	3.89e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAK2—Crohn's disease	3.71e-05	0.000134	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—Crohn's disease	3.71e-05	0.000134	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—Crohn's disease	3.39e-05	0.000123	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—Crohn's disease	3.22e-05	0.000117	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—Crohn's disease	3.14e-05	0.000114	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—Crohn's disease	2.97e-05	0.000108	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—Crohn's disease	2.83e-05	0.000102	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—Crohn's disease	2.72e-05	9.86e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—Crohn's disease	2.48e-05	8.96e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—Crohn's disease	2.4e-05	8.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—Crohn's disease	2.19e-05	7.93e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—Crohn's disease	2.1e-05	7.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—Crohn's disease	1.9e-05	6.89e-05	CbGpPWpGaD
